Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Moodys
Novartis
Farmers Insurance
Baxter
UBS
Medtronic
Colorcon
Queensland Health
US Army

Generated: December 11, 2017

DrugPatentWatch Database Preview

TEGRETOL Drug Profile

« Back to Dashboard

Which patents cover Tegretol, and when can generic versions of Tegretol launch?

Tegretol is a drug marketed by Novartis and is included in four NDAs.

The generic ingredient in TEGRETOL is carbamazepine. There are twenty-seven drug master file entries for this compound. Forty-one suppliers are listed for this compound. Additional details are available on the carbamazepine profile page.

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
NovartisTEGRETOLcarbamazepineSUSPENSION;ORAL018927-001Dec 18, 1987ABRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
NovartisTEGRETOL-XRcarbamazepineTABLET, EXTENDED RELEASE;ORAL020234-001Mar 25, 1996ABRXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
NovartisTEGRETOLcarbamazepineTABLET, CHEWABLE;ORAL018281-001Approved Prior to Jan 1, 1982ABRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
NovartisTEGRETOLcarbamazepineTABLET;ORAL016608-001Approved Prior to Jan 1, 1982ABRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
NovartisTEGRETOL-XRcarbamazepineTABLET, EXTENDED RELEASE;ORAL020234-003Mar 25, 1996ABRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
NovartisTEGRETOL-XRcarbamazepineTABLET, EXTENDED RELEASE;ORAL020234-002Mar 25, 1996ABRXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: TEGRETOL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
NovartisTEGRETOLcarbamazepineSUSPENSION;ORAL018927-001Dec 18, 1987► Subscribe► Subscribe
NovartisTEGRETOLcarbamazepineTABLET;ORAL016608-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
NovartisTEGRETOLcarbamazepineTABLET, CHEWABLE;ORAL018281-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for TEGRETOL

Drugname Dosage Strength RLD Submissiondate
carbamazepineExtended-release Tablets100 mgTegretol-XR12/30/2005

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Covington
Queensland Health
Deloitte
Teva
Merck
McKesson
Argus Health
US Army
Express Scripts
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot